Makenza 160 mg Tablets Makenza contains Enzalutamide, an androgen receptor inhibitor that acts directly on three steps of the androgen receptor (AR) signaling pathway. It competitively inhibits binding of androgens to ARs, inhibits AR nuclear translocation, and inhibits AR-mediated DNA binding, thereby blocking cell proliferation and inducing prostate cancer cell death. It is indicated for treating metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-sensitive prostate cancer (mCSPC).